Press release
Inflammatory Diseases Biologics Market to Reach US$ 157.31 Billion by 2033, Driven by Rising Autoimmune Prevalence and Biosimilar Expansion | DataM Intelligence
Inflammatory Diseases Biologics Market
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/inflammatory-diseases-biologics-market?jd
United States Key Industry Developments
☑️ January 2026: AbbVie reported strong continued uptake of Skyrizi and Rinvoq for psoriasis and rheumatoid arthritis, with expanded indications and biosimilar competition driving market share strategies.
☑️ January 2026: Johnson & Johnson announced positive real-world data for Tremfya in inflammatory bowel disease, reinforcing its position in the interleukin antagonist segment.
☑️ December 2025: Amgen expanded patient access programs for Enbrel biosimilars, securing additional formulary placements in major U.S. health systems amid cost pressures.
☑️ December 2025: Eli Lilly and Company highlighted growing adoption of its IL-17 and IL-23 inhibitors in dermatology clinics, supported by new clinical trial outcomes.
Japan Key Industry Developments
☑️ January 2026: Japanese regulatory authorities approved additional indications for key TNF and IL inhibitors, accelerating reimbursement and adoption in rheumatoid arthritis and ankylosing spondylitis treatments.
☑️ January 2026: Local and global players, including Takeda Pharmaceuticals, showcased advanced biologics portfolios at major rheumatology and gastroenterology conferences in Tokyo.
☑️ December 2025: Increased focus on biosimilar entry and next-generation JAK inhibitors, with several facilities reporting higher biologic utilization rates in autoimmune care.
Key Mergers and Acquisitions
✦ Eli Lilly and Company announced a definitive agreement to acquire Ventyx Biosciences for approximately US$ 1.2 billion (all-cash transaction at $14.00 per share), bolstering its oral therapies pipeline for inflammatory-mediated diseases including NLRP3 inflammasome inhibitors, with closing expected in the first half of 2026 (announced January 7, 2026).
✦ AbbVie entered advanced discussions to potentially acquire Revolution Medicines for over US$ 20 billion, targeting its pan-RAS oncology platform with potential applications in inflammatory and related pathways (reports surfaced January 7, 2026).
✦ Sanofi continued its acquisitive strategy with ongoing integration and follow-on deals in immunology, building on recent 2025 acquisitions while positioning for new inflammatory asset bolt-ons in early 2026.
Purchase the report to unlock market insights:
https://www.datamintelligence.com/buy-now-page?report=inflammatory-diseases-biologics-market
Market Segmentation Analysis
By Drug Class: Anti-Tumor Necrosis Factor (TNF) inhibitors dominate with 44.3% market share in 2024; followed by Interleukin antagonists, Janus Kinase (JAK) inhibitors, and Others.
By Disease Indication: Rheumatoid Arthritis holds the largest share at 40.3% in 2024; followed by Psoriasis, Inflammatory Bowel Disease, Ankylosing Spondylitis, and Others.
By Distribution Channel: Hospital Pharmacies lead; followed by Retail Pharmacies.
Regional Insights
North America commands the largest market share in the global Inflammatory Diseases Biologics market with 48.5% in 2024, supported by advanced healthcare infrastructure, high biologic penetration, favorable reimbursement policies, strong clinical adoption of TNF inhibitors and newer agents, and the presence of leading pharmaceutical companies driving innovation and market access.
Asia-Pacific remains the fastest-growing region with a CAGR of 7.7% in 2024, fueled by rising autoimmune disease burden, increasing healthcare expenditure, rapid biosimilar adoption, expanding access to specialty care, government initiatives for chronic disease management, and growing partnerships with global players.
Growth Drivers
✦ Escalating prevalence of rheumatoid arthritis, psoriasis, IBD, and other inflammatory conditions
✦ Dominance and sustained efficacy of TNF inhibitors with expanding biosimilar competition
✦ Advancements in interleukin antagonists and JAK inhibitors improving treatment outcomes
✦ Rising patient access through reimbursement and biosimilar affordability
✦ Strategic pipeline expansions, regulatory approvals, and regional market penetration
Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/inflammatory-diseases-biologics-market?jd
Key Players
The market includes leading companies such as Amgen Inc., Novartis Pharmaceuticals Corporation, Johnson & Johnson, Pfizer Inc., F. Hoffmann-La Roche Ltd, GSK, AbbVie, Sanofi, Eli Lilly and Company, Takeda Pharmaceuticals U.S.A., Inc., and others.
Key Highlights (Top 5 Key Players)
✦ AbbVie - Leading with Skyrizi and Rinvoq portfolios dominating psoriasis and RA markets.
✦ Johnson & Johnson - Dominating through Tremfya and Stelara in IBD and dermatology indications.
✦ Amgen Inc. - Strong in TNF inhibitors with Enbrel and emerging biosimilar leadership.
✦ Sanofi - Advancing interleukin and JAK pathways for multiple inflammatory conditions.
✦ Eli Lilly and Company - Growing rapidly with IL-17/IL-23 inhibitors in autoimmune diseases.
Unlock 360° Market Intelligence with DataM Intelligence Subscription Services:
https://www.datamintelligence.com/reports-subscription?jd
Power your decisions with real time competitor tracking, strategic forecasts, and global investment insights all in one place.
✅ Competitive Landscape Analysis
✅ Company Profile Analysis
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updates
✅ Live Market & Pricing Trends
✅ Regulatory and Supply Chain Analysis
Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Inflammatory Diseases Biologics Market to Reach US$ 157.31 Billion by 2033, Driven by Rising Autoimmune Prevalence and Biosimilar Expansion | DataM Intelligence here
News-ID: 4341538 • Views: …
More Releases from DataM Intelligence 4 Market Research LLP
Edge AI Processor Market Set for Explosive Growth to US$9.69 Billion by 2032, Le …
The Global Edge AI Processor Market reached US$2.58 billion in 2024 and is expected to reach US$9.69 billion by 2032, growing with a CAGR of 18.4% during the forecast period 2025-2032.
Market growth is driven by the explosion of IoT devices generating massive data volumes that demand low-latency on-device processing, reducing cloud dependency, costs, and privacy risks. Advancements in 5G connectivity, low-power high-performance chips, and AI integration in edge applications across…
Alpha-1 Antitrypsin Deficiency Market to Reach USD 3.32 Billion by 2033 at 14.2% …
The Alpha-1 Antitrypsin Deficiency Market was valued at US$ 0.90 billion in 2023 and reached US$ 1.02 billion in 2024. The market is projected to grow significantly, reaching US$ 3.32 billion by 2033, expanding at a CAGR of 14.2% during the forecast period 2025 to 2033. The strong growth trajectory reflects increasing awareness, improved diagnostic capabilities, and rising identification of rare genetic respiratory disorders worldwide.
Alpha-1 Antitrypsin deficiency is a genetic…
North America Leads Artificial Intelligence Market Expansion to USD 3,497.26 Bil …
The Artificial Intelligence market size was valued at USD 390.91 billion in 2025 and is projected to reach USD 3,497.26 billion by 2033, expanding at a CAGR of 30.6% from 2026 to 2033.The Global AI in Renewable Energy Market is growing due to rising demand for efficient energy management, integration of smart grids, government incentives for clean energy, and adoption of AI-driven predictive analytics to optimize renewable energy generation…
Hematologic Malignancy Therapeutics Market to Reach USD 154.32 Billion by 2033 a …
The Hematologic Malignancy Therapeutics Market reached US$ 71.80 billion in 2023, rising to US$ 77.06 billion in 2024, and is expected to reach US$ 154.32 billion by 2033, growing at a CAGR of 8.0% during the forecast period 2025 to 2033. The market is experiencing steady expansion, primarily driven by the increasing prevalence of blood cancers and continuous advancements in innovative treatment approaches.
Hematologic malignancy therapeutics focus on the treatment of…
More Releases for Disease
Protheragen Announces Disease Model Development Services to Enhance Rare Disease …
Protheragen announced the release of its disease model development services provided to enhance rare disease research. With an increasing focus on rare diseases and the need for tailored research models, Protheragen is dedicated to providing cutting-edge solutions to support this important area of medical research.
Rare diseases, which affect a small percentage of the population, pose unique challenges for researchers due to their limited understanding and lack of available treatment options.…
Biopharmaceutical Fermentation Market 2022 | Growing Morbidity of Genetic Diseas …
According to Precision Business Insights (PBI), the latest report, the biopharmaceutical fermentation market is expected to be valued at USD 10,302.1 million in 2022, growing at a 4.7% CAGR from 2022 to 2028. The growing prevalence of chronic illness, cancer, cardiac diseases, infectious diseases, antibiotic resistance, autoimmune diseases, etc., globally causes the leaning toward biopharmaceutical products, which show promising results in the research studies. Moreover, new findings by the…
Global Inflammatory Bowel Disease (IBD) Market Key Players Analysis, Disease Ind …
Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol…
Moyamoya Disease Market - A Scientometric Assessment of Disease During 2018-23
Market Highlight:
Moyamoya disease (MMD) is a chronic, cerebrovascular disease characterized by progressive stenosis in the internal carotid artery and an abnormal vascular network at the base of the brain. The stroke is one of the significant symptoms of moyamoya disease, which further leads to paralysis of the face, arms, and legs, loss of speech, and temporary loss of neurologic function of body parts, visual disturbances, headaches, developmental delay, and…
Refsum Disease Industry An Overview of A New Disease - 2018
"Refsum Disease" is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene…
Chagas Disease (Infectious Disease) Pipeline Forecast Report, H1, 2017 [MRH]
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease Market (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and…
